Skip to main content
. Author manuscript; available in PMC: 2016 Jul 19.
Published in final edited form as: Arthritis Rheum. 2013 Sep;65(9):2441–2449. doi: 10.1002/art.38044

Figure 1.

Figure 1

Reasons for failure to achieve the primary outcome in the Rituximab in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis trial, by treatment group. RTX = rituximab; CYC/AZA = cyclophosphamide followed by azathioprine; BVAS/WG = Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis.